Search Results - technology+classifications+%3e+life+sciences+%3e+small+molecules

48 Results Sort By:
CC16-Derived Analogs for the Treatment of Inflammatory and Obstructive Lung Diseases
This innovation relates to analogs/mimetics of CC16 also known as Urinary protein 1 (UPI), or Clara cell protein, or club cell protein. This protein is targeted for the treatment of cancer, chronic obstructive pulmonary disease, asthma, cystic fibrosis and any other diseases that CC16 may have activity in. The inventors have discovered a novel site...
Published: 6/10/2024   |   Inventor(s): Julie Ledford, Josef Vagner, Stefano Guerra, Michael Johnson
Keywords(s):  
Category(s): Technology Classifications > Life Sciences > Biologics, Technology Classifications > Life Sciences > Small Molecules, Technology Classifications > Life Sciences > Therapeutics, Technology Classifications > Healthcare Portfolios > Respiratory & Pulmonary
Compositions for Treating and Preventing Lung Disease
This invention is a novel pharmaceutical composition for supplemental expression of a protein for the treatment of asthma and other pulmonary diseases. This method utilizes a surfactant protein, delivered via aerosolization to offer a more effective treatment option. Background: Asthma medicines of the 1940’s and 1950’s consisted of epinephrine...
Published: 6/6/2024   |   Inventor(s): Julie Ledford, Monica Kraft
Keywords(s):  
Category(s): Technology Classifications > Healthcare Portfolios > Respiratory & Pulmonary, Technology Classifications > Life Sciences > Small Molecules, Technology Classifications > Life Sciences > Therapeutics
Coronavirus Therapeutics
This technology introduces a potent covalent enzyme inhibitor designed specifically for targeting the cysteine protease, PLpro, a key player in the replication process of SARS coronaviruses like SARS-CoV-2 and MERS. Unlike traditional small molecule inhibitors, this inhibitor offers unparalleled efficacy and specificity, making it a promising candidate...
Published: 6/5/2024   |   Inventor(s): Rui Xiong, Gregory Thatcher, Divakar Indukuri, Kiira Ratia, Li jun Rong
Keywords(s):  
Category(s): Technology Classifications > Healthcare Portfolios > Infectious Diseases, Technology Classifications > Healthcare Portfolios > Respiratory & Pulmonary, Technology Classifications > Life Sciences > Small Molecules, Technology Classifications > Life Sciences > Therapeutics
Broad Applications of PROTACS for Targeted Protein Degradation Employing a Molecular Glue-Linker-Warhead Approach
This technology is a high-affinity E3-ligase binder, which has been optimized toward the specific proteolysis targeting chimera (PROTAC) mediated degradation of particular proteins. A PROTAC is a heterobifunctional molecule composed of two active domains and a linker, capable of removing specific unwanted proteins. This technology opens the door for...
Published: 2/6/2024   |   Inventor(s): Christopher Hulme, Kevin Schofield
Keywords(s):  
Category(s): Technology Classifications > Life Sciences > Small Molecules, Technology Classifications > Life Sciences > Therapeutics
Bioorthogonal Activation of PROTAC Prodrugs
Utilizing proteolysis targeting chimeras (PROTACs) to degrade proteins that are important for tumorigenesis has become a potential therapeutic strategy for cancer. This innovation is an on-demand prodrug strategy called click-release proteolysis targeting chimeras, or “crPROTACs.” The crPROTACs strategy utilizes bioorthogonal chemistry and...
Published: 1/16/2024   |   Inventor(s): Wei Wang, Mengyang Chang, Giri Gnawali
Keywords(s):  
Category(s): Technology Classifications > Healthcare Portfolios > Oncology, Technology Classifications > Life Sciences > Therapeutics, Technology Classifications > Life Sciences > Small Molecules
HCV3 for Multiple Indications involving Alpha2B Receptor Modulation
The invention is a preclinical drug candidate (HCV3) based on the discovery that substituted 1-arylalkyl-4-acylaminopiperide compounds have shown to be effective antagonists of mu-, delta-, and kappa-opioid receptors and/or alpha-2-adrenoreceptors. HCV3 can be used to treat clinical conditions that are due to activation of any one or more of the receptors,...
Published: 3/12/2024   |   Inventor(s): Victor Hruby, Ruben Vardanyan
Keywords(s):  
Category(s): Technology Classifications > Life Sciences > Small Molecules, Technology Classifications > Life Sciences > Therapeutics
Redox-Activated Pro-Chelators
Novel molecular design extends the reach of iron chelators to applications in cancer chemotherapy. This invention not only recognizes the higher demand of iron that characterizes cancer cells, but also takes into account other physiological differences between malignant cells and the surrounding tissue. Specifically, pro-drugs are designed to activate...
Published: 3/12/2024   |   Inventor(s): Elisa Tomat, Eman Akam, Yu-Shien Sung
Keywords(s):  
Category(s): Technology Classifications > Life Sciences > Small Molecules, Technology Classifications > Life Sciences > Therapeutics, Technology Classifications > Healthcare Portfolios > Blood & Lymphatic Disease, Technology Classifications > Healthcare Portfolios > Oncology
Bioinspired Glycolipids as Fugitive Dust Suppression Agents
This technology involves the utilization of bioinspired glycolipids to reduce fugitive dust emissions. Background: Fugitive dust is defined by the EPA as dust that "arises from the mechanical disturbance of granular material exposed to air" and common sources of such materials include constructions sites, dirt roads, barren fields, mining...
Published: 8/23/2023   |   Inventor(s): Minkyu Kim, David Hogan, Raina Maier
Keywords(s):  
Category(s): Technology Classifications > Energy, Cleantech & Environmental, Technology Classifications > Energy, Cleantech & Environmental > Remediation > Soil, Technology Classifications > Life Sciences > Small Molecules
DYRK/CLK PROTACS
This invention describes a set of novel molecules that target and degrade DYRK/CLK for several potential therapeutic purposes. Background: Proteolysis-targeting chimeric molecules (PROTACs) are small molecules used to decrease a gene’s protein expression by targeting the protein for ubiquitination and degradation after it is created. This mechanism...
Published: 11/16/2023   |   Inventor(s): Christopher Hulme, Kevin Schofield, Walter Becker, Garrit Wilms
Keywords(s):  
Category(s): Technology Classifications > Life Sciences > Small Molecules, Technology Classifications > Life Sciences > Therapeutics
Small Molecule Chaperones of CLN1 and CLN2
The inventors here have identified a method of treating Batten Disease with small molecules that target palmitoyl-protein thioesterase 1 (PPT1), tripeptidyl peptidase 1 (TPP1), enzymes that are deficient and less active in Batten disease or Neuronal Ceroid Lipofuscinosis. The CLN1 and CLN2 genes regulate the production of these enzymes, respectively. Background: Batten...
Published: 7/12/2023   |   Inventor(s): May Khanna, Lipsa Jena
Keywords(s):  
Category(s): Technology Classifications > Life Sciences > Small Molecules, Technology Classifications > Life Sciences > Therapeutics
1 2 3 4 5